Dosage regimen of an S1P receptor modulator

Details for Australian Patent Application No. 2010300919 (hide)

Owner Novartis AG

Inventors Boulton, Craig; Burtin, Pascale; David, Olivier; De Vera, Ana; Dumortier, Thomas; Hunt, Irene; Schmouder, Robert

Agent Davies Collison Cave

Pub. Number AU-A-2010300919

PCT Pub. Number WO2011/041146

Priority 61/352,029 07.06.10 US; 61/246,706 29.09.09 US; 61/307,992 25.02.10 US; 61/258,329 05.11.09 US

Filing date 20 September 2010

Wipo publication date 7 April 2011

International Classifications

A61K 31/137 (2006.01) - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine

A61P 11/06 (2006.01) Drugs for disorders of the respiratory system

A61P 37/06 (2006.01) Drugs for immunological or allergic disorders

G06F 19/00 (2011.01) Digital computing or data processing equipment or methods, specially adapted for specific applications

Event Publications

22 March 2012 PCT application entered the National Phase

  PCT publication WO2011/041146 Priority application(s): WO2011/041146

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010300925-Novel compounds that are ERK inhibitors

2010300918-Method and system for accessing patient data